asa glp-1 The 2023 position on receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on glp 1 asa GLP-1 receptor

Hypoglycemia If youre taking a GLP-1 medication for type 2 diabetes, you might be at risk for hypoglycemia

A Phase 3 trial is expected to be completed later this year

Heres What We Know A recent question from someone with inflammatory arthritis who saw improvement while using a GLP-1 agonist brings up an interesting topic

Picking Your Most Optimal Injection Site GLP-1 medications are administered through subcutaneous injection

For comparison, nausea has been reported at approximately 44% in the Wegovy semaglutide trials and 28% in the Zepbound tirzepatide trials

Liraglutide has been shown to produce an average weight loss of around 8-10% of body weight